Jacksonville, FL and Irvine, CA – February 7, 2018 – Espero BioPharma, a platform biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the BIO CEO & Investor Conference on Tuesday, February 13th, 2018 at 10:00 AM ET. The conference will be held at the New York Marriott Marquis, in New York City.
Mr. Pham will provide a corporate overview and discuss the company’s late-stage product pipeline, including tecarfarin, Espero’s lead product candidate, and budiodarone, a potential best-in-class anti-arrhythmic agent for the treatment of refractory atrial fibrillation. Tecarfarin has the potential to be the oral anticoagulant therapy of choice for the 3.7 million patients in the United States who require anticoagulation with a Vitamin K antagonist such as warfarin, including patients with prosthetic heart valves, recurrent deep vein thrombosis or patients with chronic kidney disease, which complicates anticoagulant therapy.
The company plans to initiate The Tecarfarin for Anticoagulation Trial (TACT) in the second quarter of 2018 under an FDA-approved Special Protocol Assessment, with interim data anticipated in the fourth quarter of 2018 and filing of a New Drug Application with the U.S. Food and Drug Administration planned for 2020.
Espero also expects to initiate its third Phase 2 clinical trial of budiodarone in the second half of 2018. Budiodarone has been shown to be effective in significantly reducing atrial fibrillation burden and is being further evaluated as a novel anti-arrhythmic agent for the treatment of refractory atrial fibrillation.
About Espero BioPharma, Inc.
Espero BioPharma, Inc. is a platform biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases. The Company has offices located in Jacksonville, FL and Irvine, CA. Additional information about Espero BioPharma is available at www.esperobio.com.
Investor Relations Contact
Lazar Partners Ltd.
T: (212) 867-1768
Media Relations Contact
Lazar Partners Ltd.
T: (646) 871-8485